Beijing SL Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	519.4	411.96	683.83	595.04	827.84
Short-Term Investments	-	1,089	840.62	713.36	646.23
Trading Asset Securities	498.95	480.86	608.56	144.91	162.36
Cash & Short-Term Investments	1,018	1,982	2,133	1,453	1,636
Cash Growth	-48.63%	-7.07%	46.77%	-11.19%	13.41%
Accounts Receivable	80.93	105.79	200.57	254.86	357.56
Other Receivables	14.07	15.65	35.25	31.35	21.6
Receivables	95	121.44	235.82	286.2	379.16
Inventory	681.81	246.33	144.46	136.82	124.83
Other Current Assets	298.8	138.8	126.69	121.34	157.31
Total Current Assets	2,094	2,489	2,640	1,998	2,298
Property, Plant & Equipment	541.53	514.24	503.34	527.3	604.01
Long-Term Investments	1,573	1,578	1,573	1,798	1,404
Other Intangible Assets	633.01	678.58	693.77	526.36	479.46
Long-Term Deferred Tax Assets	53.7	69.52	-	39.5	27.65
Long-Term Deferred Charges	503.88	519	451.89	454.42	394.72
Other Long-Term Assets	673.25	130.49	415.6	532.22	553.25
Total Assets	6,072	5,979	6,278	5,876	5,760
Accounts Payable	95.54	122.29	250.76	176.18	191.4
Accrued Expenses	46.48	45.82	46.93	30.32	31.8
Current Portion of Leases	-	-	-	-	0.25
Current Income Taxes Payable	2.44	0.18	0	2.61	4.48
Current Unearned Revenue	491.96	70.53	15.29	27.87	13.33
Other Current Liabilities	93.17	50.59	60.34	51.85	83.71
Total Current Liabilities	729.59	289.41	373.33	288.83	324.96
Long-Term Leases	-	-	-	-	2.22
Long-Term Unearned Revenue	41.07	44	47.04	51.38	56.23
Long-Term Deferred Tax Liabilities	112.83	64.97	47.36	56.39	50.82
Total Liabilities	883.49	398.37	467.72	396.6	434.23
Common Stock	1,027	1,027	1,027	1,027	1,027
Additional Paid-In Capital	61.55	49.62	49.62	43.85	32.58
Retained Earnings	4,114	4,482	4,710	4,396	4,265
Comprehensive Income & Other	-21.77	13.47	13.47	0.67	-12.99
Total Common Equity	5,181	5,572	5,801	5,468	5,311
Minority Interest	7.19	8.2	9.42	11.16	14.73
Shareholders' Equity	5,189	5,581	5,810	5,479	5,326
Total Liabilities & Equity	6,072	5,979	6,278	5,876	5,760
Total Debt	-	-	-	-	2.47
Net Cash (Debt)	1,018	1,982	2,133	1,453	1,634
Net Cash Growth	-48.63%	-7.07%	46.77%	-11.06%	13.67%
Net Cash Per Share	1.00	1.87	2.10	1.43	1.57
Filing Date Shares Outstanding	1,002	1,027	1,027	1,027	1,027
Total Common Shares Outstanding	1,002	1,027	1,027	1,027	1,027
Working Capital	1,364	2,199	2,267	1,709	1,973
Book Value Per Share	5.17	5.42	5.65	5.32	5.17
Tangible Book Value	4,548	4,894	5,107	4,942	4,832
Tangible Book Value Per Share	4.54	4.76	4.97	4.81	4.70
Buildings	-	434.54	437.22	430.73	452.32
Machinery	-	472.98	458.48	435.39	415.76
Construction In Progress	-	94.92	56.97	64.75	99.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.